MediWound Ltd. (NASDAQ:MDWD – Get Rating) has been assigned an average rating of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.13.
A number of brokerages have issued reports on MDWD. Zacks Investment Research downgraded MediWound from a “buy” rating to a “hold” rating in a report on Saturday, March 19th. StockNews.com began coverage on MediWound in a report on Friday, May 13th. They set a “sell” rating for the company. Aegis decreased their price target on MediWound from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 21st. Finally, Wells Fargo & Company lifted their price target on MediWound to $8.00 and gave the stock an “overweight” rating in a report on Wednesday.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in MediWound in the 3rd quarter valued at approximately $38,000. Goldman Sachs Group Inc. purchased a new stake in MediWound in the 3rd quarter valued at approximately $48,000. Marshall Wace LLP purchased a new stake in MediWound in the 1st quarter valued at approximately $93,000. Warberg Asset Management LLC purchased a new stake in MediWound in the 1st quarter valued at approximately $44,000. Finally, Millennium Management LLC purchased a new stake in MediWound in the 4th quarter valued at approximately $57,000. Institutional investors and hedge funds own 13.58% of the company’s stock.
MediWound (NASDAQ:MDWD – Get Rating) last released its earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). MediWound had a negative net margin of 57.03% and a negative return on equity of 3,540.43%. During the same period in the previous year, the business earned ($0.10) earnings per share. As a group, equities research analysts predict that MediWound will post -0.39 earnings per share for the current fiscal year.
About MediWound (Get Rating)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.